Structure-hepatic disposition relationships for phenolic compounds

Toxicology and Applied Pharmacology

Volumn 158, Issue 1, 1999, Pages 50-60

  Mellick, George D ^a   Roberts, Michael S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PHENOL DERIVATIVE;

ANIMAL CELL; ARTICLE; BIOTRANSFORMATION; CELL MEMBRANE TRANSPORT; CHEMICAL STRUCTURE; CYTOTOXICITY; FEMALE; LIPOPHILICITY; LIVER CELL; LIVER PERFUSION; NONHUMAN; PARTITION COEFFICIENT; PH; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALIA;

EID: 0033168932     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8682     Document Type: Article

References (55)

1. Albert A., Serjeant E. P. The Determination of Ionization Constants: A Laboratory Manual. 1984;Chapman and Hall, London.
2. Ballinger L. N., Cross S. E., Roberts M. S. Availability and mean transit times of phenol and its metabolites in the isolated perfused rat liver: Normal and retrograde studies using tracer concentrations of phenol. J. Pharm. Pharmacol. 47:1995;949-956.
3. Campbell N. R. C., Van Loon J. A., Sundaram R. S., Ames M. M., Hansch C., Weinshilboum R. Human and rat liver phenol sulfotransferase: Structure-activity relationships for phenolic substrates. Mol. Pharmacol. 32:1987;813-819.
4. Cassidy M. K., Houston J. B. In vivo capacity of hepatic and extrahepatic enzymes to conjugate phenol. Drug Metab. Dispos. 12:1984;619-624.
5. Chou C. H., Evans A. M., Fornasini G., Rowland M. Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver. Drug. Metab. Dispos. 21:1993;933-938.
6. Chou C. H., McLachlan A. J., Rowland M. Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-Ethyl barbituric acid and other compounds. J. Pharm. Exp. Ther. 275:1995;933-940.
7. De Vries M. H., Groothuis G. M. M., Mulder G. J., Nguyen H., Meijeer D. K. F. Secretion of the organic anion harmol sulphate from the liver into blood. Biochem. Pharmacol. 34:1985;2129-2135.
8. Dura G., Krasovski G. N., Zholdakova Z. I., Mayer G. Prediction of toxicity using quantitative structure-activity relationships. Arch. Toxicol. Suppl. 8:1985;481-487.
9. Evans A. M. Membrane transport as a determinant of the hepatic elimination of drugs and metabolites. Clin. Exp. Pharmacol. Physiol. 23:1996;970-974.
10. Evans A. M., Hussein Z., Rowland M. Influence of albumin on the distribution and elimination kinetics of diclofenac in the isolated perfused rat liver: Analysis by the impulse-response technique and the dispersion model. J. Pharm. Sci. 82:1993;421-428.
11. Fisher H. I., Sumler M. R., Shirivastava S. P., Edwards B., Oglesby L. A., Ebron-McCoy M. T., Copeland F., Kavlock R. J., Hall L. L. Toxicokinetics and structure-activity relationships of nine para-substituted phenols in rat embryos in vitro. Teratology. 48:1993;285-297.
12. Goresky C. A., Pang K. S., Schwab A. J., Barker F. III, Cherry W. F., Bach G. G. Uptake of protein-bound polar compound, acetaminophen sulfate, by perfused rat liver. Hepatology. 16:1992;173-190.
13. Hinderling P. H., Schmidlin O., Seydel J. K. Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man. J. Pharmacokin. Biopharm. 12:1984;263-287.
14. Hirom P. C., Millbur P., Smith R. L., Williams R. T. Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem. J. 129:1972;1071-1077.
15. Hiura M., Nakagawa S., Kawashima H., Kaneniwa N. Effect of lipid solubility on hepatic first pass metabolism of barbiturates in rabbits. Int. J. Pharmaceut. 20:1984;73-85.
16. Hinz R. S., Lorence C. R., Hodson C. D., Hansch C., Hall L. L., Guy R. H. Percutaneous penetration of para-substituted phenols in vitro. Fundam. Appl. Toxicol. 47:1991;869-892.
17. Hughes M. F., Hall L. L. In vivo disposition of p-substituted phenols in the young rat after intraperitoneal and dermal administration. Food Chem. Toxicol. 35:1997;696-704.
18. Hung D. Y., Mellick G. D., Anissimov Y. G., Weiss M., Roberts M. S. Hepatic structure-pharmacokinetic relationships: The hepatic disposition and metabolite kinetics of a homologous series of O-acyl derivatives of salicylic acid. Brit. J. Pharmacol. 124:1998a;1475-1483.
19. Hung D. Y., Mellick G. D., Weiss M., Roberts M. S. The hepatic disposition and metabolite kinetics of a homologous series of diflunisal esters. J. Pharm. Sci. 1998b.
20. Hussein Z., McLachlan A. J., Rowland M. Distribution kinetics of salicylic acid in the isolate perfused rat liver assessed using moments analysis and the two-compartment axial dispersion model. Pharm. Res. 11:1994;1337-1345.
21. Kaliszan R., Pankowski M., Szymula L., Lamparczyk H., Nasal A., Tomaszewska B., Grzybowski J. Structure-olfactory activity relationships in a group of substituted phenols. Pharmazie. 37:1992;499-501.
22. Kortum G., Vogel W., Andrussow K. Dissociation Constants of Organic Acids in Aqueous Solution. 1961.
23. Reynolds J. E. F. Matindale: The Extra Pharmacopoeia. 1993;The Pharmaceutical Press, London.
24. Menon G. K., Lee S. H., Roberts M. S. Ultrastructural effects of some solvents and vehicles on the stratum corneum and other skin components: Evidence for an "Extended Mosaic-Partitioning Model of the skin barrier" Roberts M. S., Walters K. A. Dermal Absorption and Toxicity Assessment. 1998;Dekker, New York.
25. Mellick, G. D. 1996, Studies on the Disposition of Solutes in the Perfused Rat Liver and the Influence of Physicochemical Properties. Doctoral thesis, University of Queensland.
26. Mellick G. D., Roberts M. S. The disposition of aspirin and salicylic acid in the isolated perfused rat liver: The effect of normal and retrograde flow on availability and mean transit time. J. Pharm. Pharmacol. 48:1996;738-743.
27. Miyauchi S., Sugiyama Y., Sawada Y., Morita K., Iga T., Hanano M. Kinetics of hepatic transport of 4-methylumbelliferone in rats: Analysis by multiple indicator dilution method. J. Pharmacokin. Biopharm. 15:1987;25-38.
28. Oglesby L. A., Ebron-McCoy M. T., Logsdon T. R., Copeland F., Beyer P. E., Kavlock R. J. In vitro embryotoxicity of a series of para-substituted phenols: Structure, activity and correlation with in vivo data. Teratology. 45:1992;11-33.
29. Purves R. D. Optimal numerical integration methods for estimation of area-under-the-curve (AUC) and area-under-the-moments-curve (AUMC). J. Pharmacokin. Biopharm. 20:1992a;211-226.
30. Purves R. D. Bias and variance of extrapolated tail areas for area-under-the-curve (AUC) and area-under-the-moments-curve (AUMC). J. Pharmacokin. Biopharm. 20:1992b;501-510.
31. Purves R. D. Accuracy of numerical inversion of Laplace transformations for pharmacokinetic parametric estimations. J. Pharm. Sci. 84:1995;71-74.
32. Ritschel W. A., Hammer G. V. Prediction of the volume of distribution from in vitro data and use for estimating the absolute extent of absorption. Int. J. Clin. Pharmacol. Ther. Toxicol. 18:1980;298-316.
33. Roberts, M. S. 1976, Percutaneous Absorption of Phenolic Compounds. Doctoral thesis, University of Sydney.
34. Roberts M. S. Structure-permeability considerations in percutaneous absorption. Scott R. C., Guy R. H., Hadgraft J., Bodde H. E. Prediction of Percutaneous Penetration-Methods. Measurement and Modelling. 1991;210-228 IBC Technical Services, London.
35. Roberts M. S., Anderson R. A., Swarbrick J. Permeability of human epidermis to phenolic compounds. J. Pharm. Pharmacol. 29:1977;677-683.
36. Roberts M. S., Rowland M. Hepatic elimination-dispersion model. J. Pharm. Sci. 74:1985;585-587.
37. Roberts M. S., Rowland M. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm. 14:1986a;227-260.
38. Roberts M. S., Rowland M. A dispersion model of hepatic elimination: 2. Steady-state considerations-influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity. J. Pharmacokinet. Biopharm. 14:1986b;261-288.
39. Roberts M. S., Rowland M. A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics. J. Pharmacokinet. Biopharm. 14:1986c;289-308.
40. Roberts M. S., Rowland M. Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: Analysis with a dispersion model. J. Pharm. Pharmacol. 38:1986d;177-181.
41. Roberts M. S., Donaldson J. D., Rowland M. Models of hepatic elimination: Comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity and systemic recycling on hepatic elimination. J. Pharmacokin. Biopharm. 16:1988;41-83.
42. Roberts M. S., Fraser S., Wagner A., McLeod L. Residence time distributions of solutes in the perfused rat liver using a dispersion model of hepatic elimination 1. Effect of changes in perfusate flow and albumin concentration on sucrose and taurocholate. J. Pharmacokin. Biopharm. 18:1990;209-234.
43. Roberts M. S., Ballinger L. N., Weiss M. Relative dispersions of intra-albumin transit times across perfused rat and elasmobranch livers and implications on intra- and inter-species scaling of hepatic clearance using microsomal data. J. Pharm. Pharmacol. 50:1998;865-870.
44. Rowland M., Tozer T. N. Clinical Pharmacokinetics: Concepts and Applications, 3rd ed. 1995;Williams and Wilkins, Baltimore.
45. Rogers J. A., Davis S. S. Functional group contributions to the partitioning of phenols between liposomes and water. Biochim. Biophys. Acta. 598:1980;392-404.
46. a) in selecting models of toxicity in phenols. Ecotoxicol. Environ. Saf. 14:1987;178-183.
47. Toon S., Rowland M. Quantitative structure pharmacokinetic activity relationships with some tetracyclines. J. Pharm. Pharmacol. 31:1979;43.
48. Toon S., Rowland M. Structure-pharmacokinetic relationships among the barbiturates in the rat. J. Pharmacol. Exp. Ther. 225:1983;752-763.
49. Watari N., Sugiyama Y., Kaneniwa N., Hiura M. Prediction of hepatic first-pass metabolism and plasma levels following intravenous and oral administration of barbiturates in the rabbit based on quantitative structure-pharmacokinetic relationships. J. Pharmacokin. Biopharm. 16:1988;279-301.
50. Weiss M., Stedtler C., Roberts M. S. On the validity of the dispersion model of hepatic drug elimination when intravascular transit time densities are long-tailed. Bull. Math. Biol. 59:1997;911-929.
51. Weitering J. G., Krijgsheld K. R., Mulder G. J. The availability of inorganic sulphate as a rate limiting factor in the sulphate conjugation of xenobiotics in the rat. Sulphation and glucuronidation of phenol. Biochem. Pharmacol. 28:1979;757-762.
52. Williams P. L., Brooks J. D., Inman A. O., Monteiro-Riviere N. A., Riviere J. E. Determination of physicochemical properties of phenol, p-nitrophenol, acetone and ethanol relevant to quantitating their percutaneous absorption in porcine skin. Res. Commun. Chem. Pathol. Pharmacol. 83:1994;61-75.
53. Yano Y., Yamaoka K., Aoyama Y., Tanaka H. Two-compartment dispersion model for analysis of organ perfusion system of drugs by fast inversion Laplace transformation (FILT). J. Pharmacokin. Biopharm. 17:1989;179-202.
54. Yano Y., Yamaoka K., Minamide T., Nakagawa T., Tanaka H. Evaluation of protein binding effect on local disposition of oxacillin in rat liver by a two-compartment dispersion model. J. Pharm. Pharmacol. 42:1990;632-636.
55. Zhao F., Mayura K., Hutchinson R. W., Lewis R. P., Burghardt R. C., Phillips T. D. Developmental toxicity and structure-activity relationships of chlorophenols using human embryonic palatal mesenchymal cells. Toxicol. Lett. 78:1995;35-42.